Anti-PD-1 antibody in combination with radiotherapy as first-line therapy for unresectable intrahepatic cholangiocarcinoma

Table 2 Summary of endpoints: overall response and survival

Variable	Patients (n=36)
Overall response
Complete response	4 (11.1)
Partial response	18 (50.0)
Stable disease	9 (25.0)
Progressive disease	5 (13.9)
Objective response rate	61.1 (43.5-76.9)
Disease control rate	86.1 (70.5-95.3)
One-year progression-free survival rate	44.4 (30.8-64.0)
Median overall survival, months	22.0 (15.0-not estimable)
Median progression-free survival, months	12.0 (7.5-not estimable)

Data are n (%) or n (% [95% CI]), unless specified otherwise. Complete response and partial response were confirmed on a follow-up scan more than 4 weeks after an initial evaluation according to RECIST v1.1
CI confidence interval

ISSN: 1741-7015